Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Abstract: During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Leukemia. - 32 (2018) , 1542–1560, ISSN: 1476-5551
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- Creator
- DOI
-
10.1038/s41375-018-0040-1
- URN
-
urn:nbn:de:bsz:25-freidok-1751079
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ludwig, Heinz
- Engelhardt, Monika
- Sonneveld, Pieter
- Universität
Time of origin
- 2021
Other Objects (12)
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Untersuchung zur Zusammensetzung und Abstammung von Peritoneal- und Pleurazellen bei der B10D2-Maus
Veränderungen der Telomerlänge und Telomeraseaktivität bei der malignen Zellentartung und die mögliche Bedeutung der Telomerhomöostase für die Transplantation hämatopoetischer Stammzellen
Engelhardt, Monika geb. 1942 Halsschmuck "Dächerkette". 1978
Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience
Is immunotherapy here to stay in multiple myeloma?
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Untersuchung zur Zusammensetzung und Abstammung von Peritoneal- und Pleurazellen bei der B10D2-Maus
Veränderungen der Telomerlänge und Telomeraseaktivität bei der malignen Zellentartung und die mögliche Bedeutung der Telomerhomöostase für die Transplantation hämatopoetischer Stammzellen
Engelhardt, Monika geb. 1942 Halsschmuck "Dächerkette". 1978
Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience
Is immunotherapy here to stay in multiple myeloma?
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Untersuchung zur Zusammensetzung und Abstammung von Peritoneal- und Pleurazellen bei der B10D2-Maus
Veränderungen der Telomerlänge und Telomeraseaktivität bei der malignen Zellentartung und die mögliche Bedeutung der Telomerhomöostase für die Transplantation hämatopoetischer Stammzellen
Engelhardt, Monika geb. 1942 Halsschmuck "Dächerkette". 1978
Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Allogeneic stem cell transplantation in multiple myeloma
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience